Cancer Survivorship Issues in Older Adults

  • Karim S. Malek
  • Rebecca A. Silliman


Advancing age comes bundled with increased cancer incidence and mortality.1,2 Indeed, the median age at diagnosis of all cancers combined is 69 years for men and 67 years for women.3 Age-adjusted cancer incidence is ten times higher in the 65+ population compared to their younger counterparts (2,151.2 versus 208.8/100,000 persons).2 Similarly, age-adjusted cancer mortality is 15-fold higher in the 65+ population (1,068.2 versus 67.3/100,000 persons).2 Figures 16.1 and 16.2 illustrate the proportions of the commonest cancers incidence and mortality in the 65+ population.2 As a result, while the total US population is expected to grow by 9% between 1990 and 2010, the incidence of cancer is expected to increase by a disproportionate 32% in the same timeframe.4,5 These trends are mirrored in countries across the globe.6,7


Breast Cancer Breast Cancer Patient Cancer Survivor Clin Oncol Breast Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ries L, Eisner M, Kosary C, et al. Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review 1975–2000. Vol. 2003; National Cancer Institute, 2003.Google Scholar
  2. 2.
    Ries L, Kosary C, Hankey B. SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute, 1999.Google Scholar
  3. 3.
    Miller B, Ries L, Hankey B, Kosary C, Edwards B. Cancer Statistics Review 1973–1989: National Cancer Institute, 1992.Google Scholar
  4. 4.
    Kennedy B, Bushhouse S, Benber A. Minnesota population cancer risks. Cancer 1994;73:724–729.PubMedGoogle Scholar
  5. 5.
    Mettlin C. New evidence of progress in the National Cancer Program. Cancer 1996;78:2043–2044.PubMedGoogle Scholar
  6. 6.
    Levi F, Vecchia CL, Lucchini F, et al. Worldwide trends in cancer mortality in the elderly, 1955–1992. Eur J Cancer 1996;32A:652–672.PubMedGoogle Scholar
  7. 7.
    Vecchia CL, Levi F, Lucchini F, et al. International perspectives of cancer and aging. In: Balducci L, Lyman G, Ershler W (eds). Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publishers, 1998:19–93.Google Scholar
  8. 8.
    Sargent D, Goldberg R, Jacobson S, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091–1097.PubMedGoogle Scholar
  9. 9.
    Schild S, Stella P, Geyer S, et al. The outcome of combined-modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003;21:3201–3206.PubMedGoogle Scholar
  10. 10.
    Silliman RA. What constitutes optimal care for older women with breast cancer? J Clin Oncol 2003;21:3554–3556.PubMedGoogle Scholar
  11. 11.
    Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003;21:3580–3587.PubMedGoogle Scholar
  12. 12.
    Yee K, Pater J, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618–1623.PubMedGoogle Scholar
  13. 13.
    Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Under-representation of patients 65 years of age or older in cancer-treatment trials. N Eng J Med 1999;341:2061–2067.Google Scholar
  14. 14.
    Monfardini S, Sorio R, Boes G, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development studies. Cancer 1995;76:333–338.PubMedGoogle Scholar
  15. 15.
    Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383–1389.PubMedGoogle Scholar
  16. 16.
    Current population reports, special studies: 65+ in the United States. Washington, DC: US Bureau of the Census, 1996:2–8.Google Scholar
  17. 17.
    United States life tables, 2000. Natl Vital Stat Rep 2002;51:1–38.Google Scholar
  18. 18.
    Record high life expectancy. Stat Bull Metrop Insur Co 1993;74:28–35.Google Scholar
  19. 19.
    Moroff S, Pauker S. What to do when the patient outlives the literature, or DEALE-ing with a full deck. Medical Decision Making 1983;3:313–338.PubMedGoogle Scholar
  20. 20.
    Fried L, Wallace R. The complexity of chronic illness in the elderly: From clinic to community. In: Wallace R, Woolson R (eds). The Epidemiologic Study of the Elderly. New York: Oxford University Press, Inc, 1992:10–19.Google Scholar
  21. 21.
    Yancik R, Wesley M, Ries L. Comorbidity and age as predictors of risk for early mortality in male and female colon cancer patients: a population-based study. Cancer 1998;82:2123–2134.PubMedGoogle Scholar
  22. 22.
    Satariano W, Ragland D. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104–110.PubMedGoogle Scholar
  23. 23.
    Satariano W. Comorbidities and cancer. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:477–499.Google Scholar
  24. 24.
    Mandeblatt J, Bierman A, Gold K, Silliman R. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 2001;36:1085–1107.Google Scholar
  25. 25.
    Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.PubMedGoogle Scholar
  26. 26.
    Wang P, Walker A, Tsuang M, Orav E, Levin R, Avron J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000;53:571–578.PubMedGoogle Scholar
  27. 27.
    Monfardini S, Ferrucci L, Fratino L, Lungo ID, Serraino D, Zagonel V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395–401.PubMedGoogle Scholar
  28. 28.
    Reuben D. Principles of geriatric assessment. In: Hazzard W, Blass J, Ouslander J, Tinetti M (eds). Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill, 2003:99–110.Google Scholar
  29. 29.
    Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 2000;14:221–227.PubMedGoogle Scholar
  30. 30.
    Moore AA, Siu AL. Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument [see comment]. Am J Med 1996;100:438–443.PubMedGoogle Scholar
  31. 31.
    Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 2003;97:1107–1114.PubMedGoogle Scholar
  32. 32.
    Greenblatt D, Sellers E, Shader R. Drug therapy: drug disposition in old age. New Engl J Med 1982;306:1018–1028.Google Scholar
  33. 33.
    Shaw P. Common pitfalls in geriatric drug prescribing. Drugs 1982;23:324–328.PubMedGoogle Scholar
  34. 34.
    Beers M, Ouslander J. Risk factors in geriatric drug prescribing: a practical guide to avoid problems. Drugs 1989;37:105–112.PubMedGoogle Scholar
  35. 35.
    Yancik R, Havlik R, Wesley M. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996;5:399–412.Google Scholar
  36. 36.
    Newschaffer C, Penberthy M, Lynne M, Desch C, Retchin S, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with non-metastatic breast cancer. Arch Intern Med 1996;156:85–90.PubMedGoogle Scholar
  37. 37.
    Fleming S, Pursley H, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 2005;43:132–140.PubMedGoogle Scholar
  38. 38.
    West D, Satariano W, Ragland D. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Intern Med 1996;413–419.Google Scholar
  39. 39.
    Fleming S, Rastogi A, Dmitrienko A, Johnson K. A comprehensive index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999;37:601–614.PubMedGoogle Scholar
  40. 40.
    Yancik R, Wesley M, Ries M, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885–892.PubMedGoogle Scholar
  41. 41.
    Havlick R, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74(suppl):2101–2106.Google Scholar
  42. 42.
    Silliman R, Lash T. Comparison of interview-based and medical record-based indices of comorbidity among breast cancer patients. Med Care 1999;37:339–349.PubMedGoogle Scholar
  43. 43.
    Deyo R, Cherkin D, Clol M. Adapting a clinical comorbidity index for use with ICD-9 CM-administrative databases. J Clin Epidemiol 1992;45:613–619.PubMedGoogle Scholar
  44. 44.
    Romano P, Roos L, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075–1079.PubMedGoogle Scholar
  45. 45.
    Romano P, Roos L, Jollis J. Further evidence concerning the use of clinical comorbidity index with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1085–1090.Google Scholar
  46. 46.
    Small GW. Recognizing and treating anxiety in the elderly. J Clin Psychiatry.1997;58:41–47; discussions 48–50.PubMedGoogle Scholar
  47. 47.
    Osborn DP, Fletcher AE, Smeeth L, et al. Factors associated with depression in a representative sample of 14217 people aged 75 and over in the United Kingdom: results from the MRC trial of assessment and management of older people in the community. Int J Geriatr Psychiatry. 2003;18:623–630.PubMedGoogle Scholar
  48. 48.
    Feinstein A. The pre-therapeutic classification of comorbidity in chronic diseases. J Chron Dis 1970;23:455–469.Google Scholar
  49. 49.
    Lash T, Thwin S, Horton N, Guadagnoli E, Silliman R. Multiple informants: a new method to assess comorbidity in breast cancer patients. Am J Epidemiol 2003;157:249–257.PubMedGoogle Scholar
  50. 50.
    Kaplan M, Feinstein A. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387–404.PubMedGoogle Scholar
  51. 51.
    Greenfield S, Blanco D, Elashoff R, Ganz P. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766–2770.PubMedGoogle Scholar
  52. 52.
    Bennett C, Greenfield S, Aronow H, Ganz P, Vogelzang N, Elashoff R. Patterns of care related to age of men with prostate cancer. Cancer 1991;67:2633–2441.PubMedGoogle Scholar
  53. 53.
    Lyman G. Decision analysis: a way of thinking about health care in the elderly. In: Balducci L, Lyman G, Ershler W (eds). Geriatric Oncology. Philadelphia: JB Lippincott, 1992:5–14.Google Scholar
  54. 54.
    Carney P, Miglioretti D, Yankaskas B, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168–175.PubMedGoogle Scholar
  55. 55.
    Diab S, Elledge R, Clark G. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550–556.PubMedGoogle Scholar
  56. 56.
    Walter L, Covinsky K. Cancer screening in elderly patients. A framework for individualized decision making. JAMA 2001;285:2750–2756.PubMedGoogle Scholar
  57. 57.
    Law M. Screening without evidence of efficacy [see comment]. BMJ 2004;328:301–302.PubMedGoogle Scholar
  58. 58.
    Rosenthal RA, Zenilman ME, Katlic MR (eds). Principles and Practice of Geriatric Surgery. New York: Springer-Verlag, 2001.Google Scholar
  59. 59.
    Pofahl WE, Pories WJ. Current status and future directions of geriatric general surgery. J Am Geriatr Soc 2003;51:S351–S354.PubMedGoogle Scholar
  60. 60.
    Devereaux E, Kemeny M. Surgery in the elderly oncology patient. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:153–186.Google Scholar
  61. 61.
    Evans B, Townsend C, Thompson J. Organ physiology of aging. Surg Clin North Am 1994;74:23–29.Google Scholar
  62. 62.
    Wynne H, Cope L, Mutch E, et al. The effect of aging upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;1989:297–301.Google Scholar
  63. 63.
    Mooney H, Roberts R, Cooksley W, et al. Alterations in the liver with ageing. Clin Gastroenterol 1985;14:757–771.PubMedGoogle Scholar
  64. 64.
    Rocca R. Psychosocial aspects of surgical care in the elderly patient. Surg Clin North Am 1994;74:223–243.Google Scholar
  65. 65.
    Fleisher L, Eagle K. Lowering cardiac risk in non-cardiac surgery. N Engl J Med 2001;345:1677–1682.PubMedGoogle Scholar
  66. 66.
    Marcello P, Roberts P. “Routine” preoperative studies: which studies in which patients? Surg Clin North Am 1996;76:11–23PubMedGoogle Scholar
  67. 67.
    Velanovich V. Preoperative laboratory evaluation. J Am Coll Surg 1996;183:79–87.PubMedGoogle Scholar
  68. 68.
    Kaplan E, Sheiner L, Boeckmann A, et al. The usefulness of preoperative laboratory screening. JAMA 1985;253:3576–3581.PubMedGoogle Scholar
  69. 69.
    Roizen M, Kaplan E, Schreider B, et al. The relative roles of the history and physical examination, and laboratory testing in preoperative evaluation for outpatient surgery: the “Starling” curve of preoperative laboratory testing. Anesthesiol Clin North Am 1987;5:15Google Scholar
  70. 70.
    Goldman L, Caldera D, Nussbaum S. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845–850.PubMedGoogle Scholar
  71. 71.
    Goldman L. Cardiac risks and complications of noncardiac surgery. Ann Intern Med 1983;98:504–513.PubMedGoogle Scholar
  72. 72.
    Owens W, Felts J, Jr. ES. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978;49:239–243.PubMedGoogle Scholar
  73. 73.
    Evans T. Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med 2001;345:1417–1418.PubMedGoogle Scholar
  74. 74.
    Cooper A, Doig G, Sibbald W. Pulmonary artery catheters in the critically ill: an overview using the methodology of evidence-based medicine. Crit Care Clin 1996;12:777–794.PubMedGoogle Scholar
  75. 75.
    Sandman J, Hull R, Brant R, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5–14.Google Scholar
  76. 76.
    Tobias J. Clinical practice of radiotherapy. Lancet 1992;339:159–163.PubMedGoogle Scholar
  77. 77.
    Sargent E, Burns F. Repair of radiation-induced DNA damage in rat epidermis as function of age. Rad Res 1985;102:176–181.Google Scholar
  78. 78.
    Scalliet P, Pignon T. Radiotherapy in the elderly. In: Balducci L, Lyman G, Ershler W (eds). Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood Academic Publishers, 2000;421–427.Google Scholar
  79. 79.
    Mundt A. Radiation therapy and the elderly. In: Hunter C, Johnson K, Muss H (eds). Cancer in the Elderly. New York: Dekker, 2000:187–216.Google Scholar
  80. 80.
    Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr 2003;57:305–309.PubMedGoogle Scholar
  81. 81.
    Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54:462–470.PubMedGoogle Scholar
  82. 82.
    Janda M, Johnson D, Woelfl H, et al. Measurement of quality of life in head and neck cancer patients utilizing the quality of life radiation therapy questionnaire. Strahlenther Onkol 2002;178:153–158.PubMedGoogle Scholar
  83. 83.
    Berg C, Carbone P. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986–1992.Google Scholar
  84. 84.
    Christman K, Muss H, Case L, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 1992;268:57–62.PubMedGoogle Scholar
  85. 85.
    Lichtman S, Skirvin J, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Clin Rev Oncol Hematol 2003;46:101–114.Google Scholar
  86. 86.
    Yuen G. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257–267.PubMedGoogle Scholar
  87. 87.
    Wallace S, Whiting B. Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol 1976;3:327–330.PubMedGoogle Scholar
  88. 88.
    Woodhouse K, Wynne H. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1998;15:287–294.Google Scholar
  89. 89.
    Soteniemi E, Arranto A, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331–339.Google Scholar
  90. 90.
    Vestal R. Aging and pharmacology. Cancer 1997;80:1302–1310.PubMedGoogle Scholar
  91. 91.
    Lindeman R, Tobin J, Shock N, et al. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278–285.PubMedGoogle Scholar
  92. 92.
    Cockroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–42.Google Scholar
  93. 93.
    Lipschitz D. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995;22(suppl):3–5.PubMedGoogle Scholar
  94. 94.
    Ibrahim N, Frye D, Buzdar A, et al. Docorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 1996;156:882–888.PubMedGoogle Scholar
  95. 95.
    Fisher R, Graynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328:1002–1006.PubMedGoogle Scholar
  96. 96.
    Lyman G, Kuderer D, Djulbegovic B. Prophylactic granulocyte colony-stimulating factors in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406–411.PubMedGoogle Scholar
  97. 97.
    Balducci L, Lyman G. Patients aged ≥70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001;19:1583–1585.PubMedGoogle Scholar
  98. 98.
    Ozer H, Armitage J, Bennett C, et al. 2000 Update of recommendations for the use of Hematopoietic Colony-Stimulating Factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558–3585.PubMedGoogle Scholar
  99. 99.
    Chavez P, Volpato S, Fried L. Challenging the World Health Organization criteria for anemia in older women. J Am Geriatr Soc 2001;49(suppl 3):10.Google Scholar
  100. 100.
    Izaks G, Westendorp R, Knoot D. The definition of anemia in older persons. JAMA 1999;281:1714–1717.PubMedGoogle Scholar
  101. 101.
    Kikuchi M, Inagaki T, Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Geriatr Soc 2001;49:1226–1228.PubMedGoogle Scholar
  102. 102.
    Gutstein H. The biologic basis of fatigue. Cancer 2001;92(suppl):1678–1683.PubMedGoogle Scholar
  103. 103.
    Nissenson A. Epoetin and cognitive function. Am J Kidney Dis 1992;20(suppl):21–24.PubMedGoogle Scholar
  104. 104.
    Shrijvers D, Highley M, Bruyn ED, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999;10:147–153.Google Scholar
  105. 105.
    Rizzo J, Lichtin A, Woolf S, et al. Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;19:4083–4107.Google Scholar
  106. 106.
    Hellstrom-Lindberg E, Ahlgren T, Begguin Y, et al. Treatment of the anemia of myelodysplastic syndromes with G-CSF plus erythoropoietin: Results of a randomized phase II study and long term follow-up of 71 patients. Blood 1998;92:68–75.PubMedGoogle Scholar
  107. 107.
    Popescu R, Norman A, Ross P, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412–2418.PubMedGoogle Scholar
  108. 108.
    Sargent D, Goldberg R, MacDonald J, et al. Adjuvant chemotherapy for colon cancer (CC) is beneficial without significant incrased toxicity in elderly patients (Pts): results from 3351 Pt meta-analysis [Abstract 933]. Proc Am Soc Clin Oncol 2000;19:241a.Google Scholar
  109. 109.
    Cancer control and population sciences: research findings. Accessed August 1, 2005.Google Scholar
  110. 110.
    Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implication of age and aging on US cancer burden. Cancer 2002;94:2766–2792.PubMedGoogle Scholar
  111. 111.
    National Center for Health Statistics. Life Tables of the United States, 1997.Google Scholar
  112. 112.
    Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol 2003;58:82–91.Google Scholar
  113. 113.
    Stafford RS, Cyr PL. The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer 1997;80:1973–1980.PubMedGoogle Scholar
  114. 114.
    Smith TJ, David NE, Schapira DV, et al: American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;47:1080–1082.Google Scholar
  115. 115.
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: follow-up after treatment for breast cancer. Can Med Assoc J 1998;158(S3):S65–S70.Google Scholar
  116. 116.
    Report from the National Breast Cancer Consensus Conference. Management of newly diagnosed early breast cancer: A national approach to breast cancer control. Med J Aust 1994;161(S7):S10–S16.Google Scholar
  117. 117.
    The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994;271:1587–1592.Google Scholar
  118. 118.
    Roselli Del Turco M, Palli D, Criddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. JAMA 1994;271:1593–1597.Google Scholar
  119. 119.
    Shapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA 1991;265:380–382.Google Scholar
  120. 120.
    Schapira MM, McAulliffe TL, Nattinger AB. Underutilization of mammography in older breast cancer survivors. Med Care 2000;38:281–289.PubMedGoogle Scholar
  121. 121.
    Lash TL, Silliman RA. Medical surveillance after breast cancer diagnosis. Med Care 2001;39:945–955.PubMedGoogle Scholar
  122. 122.
    Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, van Walraven C, et al. Surveillance mammography after treatment of primary breast cancer. A systematic review. Breast 2002;11:228–235.PubMedGoogle Scholar
  123. 123.
    Westrup JL, Lash TL, Thwin SS, Silliman RA. Risk of decline in upper-body function and symptoms among older breast cancer patients. J Gen Intern Med; under review.Google Scholar
  124. 124.
    Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol 1998;53A:M372–M378.Google Scholar
  125. 125.
    Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of nonbreast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003;21:1447–1451.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Karim S. Malek
    • 1
  • Rebecca A. Silliman
    • 2
    • 3
  1. 1.Department of Medicine, Section of Hematology and OncologyBoston University School of MedicineBostonUSA
  2. 2.Department of Medicine and Public HealthBoston University School of MedicineUSA
  3. 3.Section of GeriatricsBoston University School of Medicine, Boston Medical CenterBostonUSA

Personalised recommendations